Move to topTop
Johannesburg, South-Africa – Terumo Corporation (TSE: 4543) today announced the establishment of Terumo South Africa (Pty) Ltd. (Terumo South Africa), its newest subsidiary in South-Africa. This strategic move represents a significant milestone in the company’s continued commitment to expanding its global footprint and strengthening its presence in key growing markets.
Terumo South Africa, established as a wholly owned subsidiary of Terumo Europe and located in the heart of Johannesburg, will serve as a vital hub for Terumo to directly connect with local partners, better serve its growing customer base, and meet the healthcare needs and demands of South-Africa by providing tailored solutions, localized support, and rapid responses to the ever-evolving market conditions.
It is a first step in developing the company’s footprint in Africa to further strengthen its presence on the continent.
Takuya Hosogai, President and CEO of Terumo Europe, said, “The opening of our new subsidiary in South-Africa is a step forward in realising our global Growth Strategy. We are dedicated to delivering exceptional value to our South-African partners, customers, and the patients they serve.” 
Khalil Aswad, General Manager, Africa, Terumo Interventional Systems, added, “Opening Terumo South Africa will enable us to engage closely with our customers, understanding their unique requirements and contributing to the local society through healthcare.”

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.